Natriumvalproaat Chrono Teva (Valproic Acid, Sodium Valproate)

Valproic acid raises brain levels of the inhibitory neurotransmitter GABA by inhibiting its breakdown and enhancing its synthesis. It also blocks voltage‑gated sodium channels, which together dampen excessive neuronal firing and lower the risk of seizures and mood swings.

The appropriate dose of Natriumvalproaat Chrono Teva is individualized by the prescribing clinician based on the patient’s age, weight, indication, and response to therapy. Dosage adjustments are made according to therapeutic drug monitoring and clinical judgement.

Valproic acid is classified as Pregnancy Category D, indicating evidence of fetal risk. It should be avoided in pregnancy unless no suitable alternative exists. Breastfeeding is not recommended because the drug is excreted in milk and may affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other anticonvulsants, valproic acid offers broad-spectrum seizure control and mood‑stabilising properties, but it carries a higher risk of liver toxicity and weight gain. Alternatives such as carbamazepine or lamotrigine may have different side‑effect profiles, so choice depends on individual patient factors.

Store Natriumvalproaat Chrono Teva at room temperature, below 25 °C, in the original container. Keep it away from moisture, direct sunlight and excessive heat to maintain product stability.

The medication is taken orally, usually with food or a glass of water to reduce gastrointestinal irritation. The exact dosing schedule—once daily or divided doses—should follow the prescriber’s instructions.

Serious risks include liver failure, acute pancreatitis, severe skin reactions such as Stevens‑Johnson syndrome, thrombocytopenia, hyperammonemic encephalopathy, and increased suicidal thoughts. Patients should be monitored regularly for these events.

Individuals with known hypersensitivity to valproic acid or any excipients, patients with severe hepatic disease, those with urea cycle disorders, and pregnant women unless no alternative exists should avoid using Natriumvalproaat Chrono Teva.